Clients
Renalytix plc
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
| Event | Date |
| Year End | 30 June |
| Half Year End | 31 December |
| Preliminary Results* | October |
| Interim Results* | March |
| AGM* | December |
* Months based on previous announcements of this kind
Renalytix - Interim Results presentation March 2025
Who We Work With
Renalytix plc
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
| Event | Date |
| Year End | 30 June |
| Half Year End | 31 December |
| Preliminary Results* | October |
| Interim Results* | March |
| AGM* | December |
* Months based on previous announcements of this kind
Renalytix - Interim Results presentation March 2025
Leave a comment